MONECO Advisors LLC Purchases 8,311 Shares of Bristol-Myers Squibb (NYSE:BMY)

MONECO Advisors LLC lifted its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 97.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,823 shares of the biopharmaceutical company's stock after purchasing an additional 8,311 shares during the period. MONECO Advisors LLC's holdings in Bristol-Myers Squibb were worth $952,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pavion Blue Capital LLC boosted its stake in shares of Bristol-Myers Squibb by 7.0% during the 4th quarter. Pavion Blue Capital LLC now owns 15,233 shares of the biopharmaceutical company's stock worth $862,000 after acquiring an additional 1,000 shares during the last quarter. Howard Capital Management Inc. raised its holdings in Bristol-Myers Squibb by 47.4% in the 4th quarter. Howard Capital Management Inc. now owns 19,949 shares of the biopharmaceutical company's stock worth $1,128,000 after purchasing an additional 6,416 shares during the period. Wealthspire Advisors LLC lifted its position in Bristol-Myers Squibb by 0.6% during the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock valued at $1,622,000 after purchasing an additional 170 shares in the last quarter. Kooman & Associates purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $209,000. Finally, TCW Group Inc. grew its holdings in Bristol-Myers Squibb by 2.0% during the fourth quarter. TCW Group Inc. now owns 37,339 shares of the biopharmaceutical company's stock valued at $2,112,000 after purchasing an additional 721 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,823 shares of Bristol-Myers Squibb stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.09% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of analyst reports. Wolfe Research started coverage on Bristol-Myers Squibb in a research report on Friday, November 15th. They set a "peer perform" rating on the stock. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Morgan Stanley upped their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a research report on Tuesday, November 12th. Daiwa America upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 13th. Finally, Leerink Partnrs raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $57.86.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $55.85 on Monday. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10. The business has a 50 day simple moving average of $56.99 and a two-hundred day simple moving average of $54.41. The stock has a market capitalization of $113.33 billion, a PE ratio of -12.63, a P/E/G ratio of 2.07 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 4.44%. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.